Chiesi Farmaceutici
Chiesi Farmaceutici, a prominent player in the global pharmaceutical industry, is headquartered in Parma, Italy. Founded in 1935, the company has established a strong presence in various operational regions, including Europe, North America, and Asia. Specialising in innovative treatments for respiratory diseases, neonatology, and rare diseases, Chiesi is renowned for its commitment to research and development, which has led to several key milestones in the biopharmaceutical sector. The company’s core products, including advanced inhalation therapies and specialty medicines, are distinguished by their focus on patient-centric solutions. Chiesi Farmaceutici has garnered recognition for its sustainable practices and dedication to improving health outcomes, positioning itself as a leader in the pharmaceutical market. With a rich history and a forward-thinking approach, Chiesi continues to make significant contributions to healthcare worldwide.
DitchCarbon Score
How does Chiesi Farmaceutici's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Chiesi Farmaceutici's score of 56 is higher than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Chiesi Farmaceutici's reported carbon emissions
In 2023, Chiesi Farmaceutici reported total carbon emissions of approximately 980,116,000 kg CO2e. This figure includes 29,906,000 kg CO2e from Scope 1 emissions, 4,000,000 kg CO2e from Scope 2 emissions, and a significant 949,619,000 kg CO2e from Scope 3 emissions, which encompasses emissions from the use of sold products and other indirect sources. Chiesi has set ambitious climate commitments, aiming for net-zero greenhouse gas emissions across its entire value chain by 2035. The company has established near-term targets to reduce absolute Scope 1 and 2 emissions by 90% by 2030, using 2019 as the baseline year. Additionally, it aims to decrease Scope 3 emissions from the use of sold products by 80% per unit of respiratory product sold by 2030, and to achieve a 90% reduction in absolute Scope 3 emissions by 2035. These targets align with the Science Based Targets initiative (SBTi) and are designed to contribute to limiting global warming to 1.5°C. Chiesi's commitment reflects a proactive approach to sustainability within the pharmaceutical sector, addressing both direct and indirect emissions comprehensively.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Get Started| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 33,911,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 15,835,000 | 0,000,000 | 0,000,000 | 000,000 | 000,000 |
| Scope 3 | 742,267,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Chiesi Farmaceutici is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
